Compare BEAT & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEAT | AYTU |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6M | 27.4M |
| IPO Year | N/A | 2015 |
| Metric | BEAT | AYTU |
|---|---|---|
| Price | $0.49 | $2.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.63 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 581.0K | 23.1K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $315.97 | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.48 | $1.65 |
| 52 Week High | $4.00 | $3.07 |
| Indicator | BEAT | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 34.10 | 57.95 |
| Support Level | N/A | $2.08 |
| Resistance Level | $0.79 | $2.31 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 8.86 | 83.33 |
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.